Alzheimer's Disease
Symptom onset, mortality linked for those with Down syndrome, autosomal dominant AD
Age variability in symptom onset of Alzheimer’s disease in those with Down syndrome was comparable to those who experienced autosomal dominant AD, while mortality was also similar, according to a study published in JAMA Network Open.
Higher antioxidant levels may lower risk for dementia
People with higher levels of antioxidants in their blood may be less likely to develop dementia, researchers reported in Neurology.
Alzamend begins phase 2 trial for lithium-based oral treatment for Alzheimer’s disease
Alzamend Neuro Inc. has announced the launch of a phase 2A trial for its AL001 treatment for mild to moderate Alzheimer’s dementia.
Indian Health Service announces funding to address Alzheimer’s in tribal communities
The Indian Health Service has announced it will allocate $5 million in funding toward resources to address Alzheimer’s disease among tribal communities.
FDA to reconvene on treatment for Alzheimer’s psychosis in June
The FDA announced it will review a resubmitted supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
FDA grants fast track designation for Alzheimer’s treatment
The FDA has granted fast track designation for Vaxxinity Inc.’s UB-311, an anti-amyloid beta immunotherapeutic vaccine, for the treatment of Alzheimer’s disease.
Together Senior Health launches platform to reduce memory loss in AD, dementia
Together Senior Health, a digital therapeutics and cognitive health firm, has announced the launch of its cognitive health platform, which it hopes will reduce the impact of memory loss in those with Alzheimer’s disease and dementia.
Medicare will only cover Aduhelm for patients enrolled in clinical trials
CMS announced that Medicare is limiting coverage of the controversial Alzheimer’s disease drug Aduhelm to participants who are enrolled in FDA- or NIH-approved clinical trials.
‘Not time to give up’ on tau protein therapeutics, expert says
SEATTLE — Although successful tau therapeutics have not yet been identified, new insights into the protein’s biology may soon lead to treatments, according to a presenter at the 2022 American Academy of Neurology annual meeting.
Cyclica, Arctoris partnership focuses on Alzheimer’s disease
Cyclica and Arctoris have expanded their partnership to progress drug discovery programs for novel neurodegenerative targets, focusing on Alzheimer’s disease, according to a press release.